EPISODE · Jun 1, 2026 · 11 MIN
May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, RevolutionMedicines, ivonescimab, Akeso, Summit Therapeutics, Pfizer, Innovent Biologics,Eli Lilly, ASCO 2026, pancreatic cancer, KRAS, RAS, lung cancer, bepirovirsen,GSK, Ionis, hepatitis B, Braftovi, Lorbrena, Talzenna, Erleada, Zepbound,Foundayo, MannKind, Afrezza, Incyte, Monjuvi, DLBCL, BMS, Retevmo, Allogene,Lilly, Novo Nordisk, Merck, J&J
What this episode covers
RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, RevolutionMedicines, ivonescimab, Akeso, Summit Therapeutics, Pfizer, Innovent Biologics,Eli Lilly, ASCO 2026, pancreatic cancer, KRAS, RAS, lung cancer, bepirovirsen,GSK, Ionis, hepatitis B, Braftovi, Lorbrena, Talzenna, Erleada, Zepbound,Foundayo, MannKind, Afrezza, Incyte, Monjuvi, DLBCL, BMS, Retevmo, Allogene,Lilly, Novo Nordisk, Merck, J&J
NOW PLAYING
May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m